Bimatoprost/timolol: A review of its use in glaucoma and ocular hypertension

Drugs and Aging

Volumn 26, Issue 2, 2009, Pages 169-184

  Curran, Monique P ^a,b   Orman, Jennifer S ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug evaluations; Bimatoprost timolol, pharmacodynamics; Bimatoprost timolol, pharmacokinetics; Bimatoprost timolol, therapeutic use; Glaucoma, treatment; Research and development

Indexed keywords

BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST PLUS TIMOLOL; TIMOLOL; TIMOLOL PLUS TRAVOPROST;

BURNING SENSATION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TOLERABILITY; EYE BURNING; EYE IRRITATION; HUMAN; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PHOTOPHOBIA; PRIORITY JOURNAL; PUNCTATE KERATITIS; REVIEW;

AMIDES; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; CLOPROSTENOL; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; GLAUCOMA; HUMANS; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL;

EID: 60249091283     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002512-200926020-00008     Document Type: Review

References (62)

1. The Royal College of Ophthalmologists. A national research strategy for ophthalmology (March 2002) [online]. Available from URL: http://www.rcophth.ac. uk/docs/publications/EyeResearchFinal.pdf [Accessed 2006 Oct 16]
2. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona, Italy: Dogma, 2008
3. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005; 22 (1): 1-21
4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002; 120: 1268-79
5. Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian glaubilcoma study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008; 126 (8): 1030-6
6. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121 (1): 48-56
7. Geringer CC, Imami NR. Medical management of glaucoma. Int Ophthalmol Clin 2008; 48 (4): 115-41
8. Fiscella RG. Pharmacological considerations in the treatment of glaucoma. Manag Care ed. 2002 Jan; 11 (1): 16-20
9. Goldberg LD. Clinical guidelines for the treatment of glaucoma. Manag Care 2002 Nov; 11 (11 Suppl.): 16-24
10. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol 2004; 15: 119-26
11. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002; 19 (3): 231-48
12. Perry CM, McGavin JK, Culy CR, et al. Latanoprost: an update on its use in glaucoma and ocular hypertension. Drugs Aging 2003; 20 (8): 597-630
13. Waugh J, Jarvis B. Travoprost. Drugs Aging 2002; 19 (6): 465-71
14. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004; 15 (2): 132-5
15. Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Opthal Sur 1995; 26 (3): 233-6
16. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007; 24 (12): 1007-16
17. Plosker GL, Keam SJ. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Pharmacoeconomics 2006; 24 (3): 297-314
18. European Agency for the Evaluation of Medicinal Products. Ganfort® : summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ganfort/ganfort.htm [Accessed 2008 May 10]
19. Allergan Inc. Lumigan® (bimatoprost ophthalmic solution) 0.03%: package insert [online]. Available from URL: http://www.lumigan.com/prescribing- information.aspx [Accessed 2008 Dec 6]
20. Merck and Co., Inc.. Timoptic® ophthalmic solution (timolol) 0.25% and 0.5%, summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=1194 [Accessed 2008 May 12]
21. Lim KS, Nau CB, O'Bryne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects: a crossover study. Ophthalmology 2008; 115 (5): 790-4
22. Christiansen GA, Nau CB, McLaren JW, et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004 Sep; 111 (9): 1658-62
23. Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res 2004 Mar; 78 (3): 639-51
24. Zeitz O, Matthiessen ET, Reuss J, et al. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. BMC Ophthalmol 2005; 5 (1): 6
25. Akarsu C, Yilmaz S, Taner P, et al. Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension. Graefe's Arch Clin Exp Ophthalmol 2004 Oct; 242 (10): 814-8
26. Woodward DF, Krauss AH-P, Chen J, et al. The pharmacology of bimatoprost (Lumigan™). Surv Ophthalmol 2001 May; 47 Suppl. 4: S337-45
27. Korte J-M, Kaila T, Matti Saari K, et al. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe's Arch Clin Exp Ophthalmol 2002; 240 (6): 430-5
28. Dickstein K, Hapnes R, Aarsland T. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol 2001 Nov; 132 (5): 626-32
29. Woodward DF, Liang Y, Krauss AH-P. Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol 2008; 153 (3): 410-9. Epub 2007 Aug 27
30. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthmol 2002; 120 (10): 1286-93
31. Rossetti L, Karabatsas CH, Topouzis F, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology 2007 Apr 23
32. European Agency for the Evaluation of Medicinal Products (EMEA). European public assessment report: scientific discussion of ganfort® [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ganfort/ ganfort.htm [Accessed 2008 May 28]
33. Phillips CJ, Bartholomew RS, Kazi G, et al. Penetration of timolol eye drops into human aqueous humour. Br J Ophthalmol 1981; 65: 593-5
34. Hommer A, Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007; 17 (1): 53-62
35. Brandt JD, Cantor LB, Katz LJ, et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008; 17 (3): 211-6
36. Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin 2007 May; 23 (5): 1025-32
37. Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye. Epub 2008 Jun 6
38. Centofanti M, Oddone F, Vertrugno M, et al. Efficacy of the fixed combination of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol 2009; 19 (1): 66-71
39. Skorkovská K. Comparison of fixed combination of bimatoprost 0.03% and timolol 0.5% with other combinations of antiglaucoma drugs in the treatment of glaucoma. Cesk Slov Oftalmol 2008; 64 (4): 144-8
40. Hommer A, Wickstrøm J, Friis MM, et al. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective. Curr Med Res Opin 2008 Apr; 24 (4): 1057-63
41. Hughes BA, Bacharach J, Craven R. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005; 14: 392-9
42. Schuman JS, Katz GJ, Lewis RA. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005; 140: 242-50
43. Barnebey HS, Orengo-Nania S, Flowers BE. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005; 140: 1-7
44. Diestelhorst M, Larsson L-I, for the European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus individual components. Ophthalmology 2006; 113: 70-6
45. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004 Nov; 82 (11): 884-51
46. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-7
47. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13
48. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol 1998; 126: 487-97
49. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505
50. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medication or surgery. Ophthalmology 2001; 108: 1943-53
51. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2001; 130: 429-40
52. American Academy of Ophthalmology. Preferred practice pattern; primary open-angle glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2005
53. McKinnon GSJ, Goldberg LD, Peeples P, et al. Current management of glaucoma and the need for complete therapy. Am J Manag Care 2008; 14: S20-7
54. Susanna RJ, Chew P, Kitazawa Y, et al. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol 2002; 47 Suppl. 1: S97-104
55. Woodward DF, Chen J. Fixed-combination and emerging glaucoma therapies. Expert Opin Emerg Drugs 2007; 12 (2): 313-27
56. Reeder CE, Franklin M, Bramely TJ. Managed care and the impact of glaucoma. Am J Manag Care 2008; 14: S5-S10
57. Broadway DC, Grierson I, O'Brien C. Adverse effects of topical antiglaucoma medication: I. The conjunctival cell profile. Arch Ophthalmol 1994; 112: 1437-45
58. Lavin MJ, Wormald RPL, Migdal CS. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990; 108: 1543-8
59. Allergan Inc. Brimonidine 0.2%/timolol 0.5% (Combigan™): prescribing information [online]. Available from URL: http://www.combigan.com/ hcp/default.aspx [Accessed 2008 Dec 2]
60. Merck and Co., Inc. Dorzolamide hydrochloride-timolol maleate ophthalmic solution (Cosopt™) [online]. Available from URL: http://www.merck.com/ product/usa/pi-circulars/c/cosopt/cosopt-pi.pdf [Accessed 2008 Dec 2]
61. Pfizer. Latanoprost 0.005%/timolol 0.5% eye drops (Xalacom®) [online]. Available from URL: www.pfizer.com.au/DisplayPI.aspx?PDFDocumentID= 340af8d0-5394-4e7a-aa79-b75f9e74566f [Accessed 2008 Dec 2]
62. Hoy S, Keam SJ, Keating GM. Travoprost/timolol. Drugs Aging 2006; 23 (7): 587-97